ProfileGDS5678 / 1424803_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 40% 40% 41% 42% 45% 39% 40% 41% 57% 42% 42% 41% 48% 47% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.9535440
GSM967853U87-EV human glioblastoma xenograft - Control 22.912140
GSM967854U87-EV human glioblastoma xenograft - Control 32.9471941
GSM967855U87-EV human glioblastoma xenograft - Control 42.9184942
GSM967856U87-EV human glioblastoma xenograft - Control 53.0031545
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.972739
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.99340
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.9386141
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.439957
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.9509442
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.9530642
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.9039441
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.146148
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.0949847